Biotechnology Ultrasector Financial Statements From 2010 to 2026
| BIPIX Fund | USD 67.30 0.18 0.27% |
Check Biotechnology Ultrasector financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biotechnology Ultrasector's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biotechnology financial statements analysis is a perfect complement when working with Biotechnology Ultrasector Valuation or Volatility modules.
Biotechnology |
Biotechnology Ultrasector Profund Mutual Fund Annual Yield Analysis
Biotechnology Ultrasector's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Current Biotechnology Ultrasector Annual Yield | 0 % |
Most of Biotechnology Ultrasector's fundamental indicators, such as Annual Yield, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotechnology Ultrasector Profund is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Biotechnology Ultrasector Profund has an Annual Yield of 0.0013%. This is much higher than that of the ProFunds family and significantly higher than that of the Trading--Leveraged Equity category. The annual yield for all United States funds is 99.55% higher than that of the company.
Biotechnology Ultrasector Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Ultrasector's current stock value. Our valuation model uses many indicators to compare Biotechnology Ultrasector value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Ultrasector competition to find correlations between indicators driving Biotechnology Ultrasector's intrinsic value. More Info.Biotechnology Ultrasector Profund is the top fund in price to earning among similar funds. It also is the top fund in price to book among similar funds fabricating about 2.19 of Price To Book per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotechnology Ultrasector's earnings, one of the primary drivers of an investment's value.About Biotechnology Ultrasector Financial Statements
Biotechnology Ultrasector investors use historical fundamental indicators, such as Biotechnology Ultrasector's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biotechnology Ultrasector. Please read more on our technical analysis and fundamental analysis pages.
The index is designed to measure the performance of biotechnology companies included in the SP Total Market Index. Under normal circumstances, the fund will obtain leveraged exposure to at least 80 percent of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Ultrasector financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Ultrasector security.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |